Mazdutide

Mazdutide: GLP-1 and Glucagon Receptor Agonist

Mazdutide, also known as IBI362, is a dual GLP-1 and glucagon receptor agonist being developed for metabolic diseases including obesity, overweight and type 2 diabetes.

Mazdutide is designed to activate both the GLP-1 receptor and the glucagon receptor. This combined mechanism is being investigated for its potential effects on appetite, body weight, glucose metabolism and other metabolic outcomes.

Important UK status: Mazdutide should not be presented on a UK website as an authorised routine prescription medicine unless current MHRA authorisation has been confirmed. Regulatory status can differ between countries and may change as clinical development progresses.

What Is Mazdutide?

Mazdutide is an investigational metabolic medicine developed through a collaboration between Innovent Biologics and Eli Lilly.

It is a long-acting peptide designed to target two receptors involved in metabolic regulation: GLP-1 and glucagon.

The dual mechanism distinguishes mazdutide from medicines that activate only the GLP-1 receptor and from dual GIP/GLP-1 medicines such as tirzepatide.

How Does Mazdutide Work?

Mazdutide is designed to activate two important metabolic pathways:

• GLP-1 receptor: GLP-1 signalling is involved in appetite regulation, food intake and glucose metabolism.
• Glucagon receptor: glucagon signalling has important effects on energy metabolism and glucose regulation and is being investigated for its potential contribution to weight management.

The purpose of combining these activities is to investigate whether dual GLP-1 and glucagon receptor activation can produce meaningful improvements in body weight and metabolic health.

Mazdutide and Weight Management Research

Mazdutide has been extensively studied in people with overweight or obesity.

Clinical development has evaluated different doses and treatment durations, with studies assessing changes in body weight, waist circumference and other metabolic measurements.

In clinical research, higher doses have produced substantial reductions in body weight compared with placebo. However, trial results should not be interpreted as guaranteed results for an individual patient.

The ongoing development programme is intended to establish the appropriate dose, long-term effectiveness and safety profile of the medicine.

Mazdutide and Type 2 Diabetes

Mazdutide has also been investigated in adults with type 2 diabetes.

Research has assessed its potential effects on blood glucose control and body weight, including HbA1c and other metabolic measurements.

Because mazdutide affects both GLP-1 and glucagon pathways, researchers are evaluating whether its dual mechanism may provide benefits across several aspects of metabolic disease.

Mazdutide Clinical Development

Mazdutide has progressed through multiple clinical development programmes investigating obesity, overweight and type 2 diabetes.

Studies have evaluated once-weekly administration at different dose levels, including research designed to assess weight reduction, cardiometabolic outcomes and long-term safety.

Clinical development has included large Phase 3 studies, providing substantially more evidence than early-stage experimental research. Nevertheless, clinical-trial development and regulatory approval are separate processes.

Is Mazdutide Approved in the UK?

Mazdutide should not currently be described as an MHRA-authorised routine UK medicine without verification of a current UK marketing authorisation.

Approval in another country does not automatically establish authorisation in the United Kingdom.

For current UK regulatory information, check the Medicines and Healthcare products Regulatory Agency (MHRA) and its published marketing-authorisation information.

Can Mazdutide Be Bought Online?

Consumers should be cautious about websites advertising mazdutide as an ordinary weight-loss medicine.

Where a medicine has not been authorised for routine UK use, products advertised online may not have been manufactured, tested or supplied through an appropriate regulated medicines supply chain.

Unverified injectable products can present risks involving identity, strength, sterility, storage and contamination.

Do not assume that a product labelled “mazdutide,” “IBI362” or “research peptide” is an authentic or clinically appropriate medicine.

Mazdutide vs Semaglutide

Ozempic (semaglutide) and Rybelsus (semaglutide) contain semaglutide, a GLP-1 receptor agonist.

Mazdutide has a different mechanism because it is designed to activate both GLP-1 and glucagon receptors.

The medicines therefore have different pharmacological profiles and should not be considered interchangeable.

Mazdutide vs Mounjaro

Mounjaro (tirzepatide) activates both GIP and GLP-1 receptors.

Mazdutide instead targets GLP-1 and glucagon receptors.

Although both are being investigated or used in the field of obesity and metabolic disease, their receptor activity is different and clinical results cannot be directly assumed to be equivalent.

Mazdutide Safety and Side Effects

As with other medicines affecting the GLP-1 pathway, gastrointestinal adverse effects can occur during clinical studies.

Reported adverse events in mazdutide studies have included symptoms such as nausea, vomiting and diarrhoea. The frequency and severity of adverse events can depend on dose and treatment stage.

Because regulatory indications and prescribing information depend on the jurisdiction and product status, patients should rely on official product information and advice from a qualified healthcare professional.

Mazdutide and Cardiometabolic Health

Clinical development has investigated more than weight reduction alone.

Researchers have evaluated effects on measurements such as waist circumference, blood glucose and other cardiometabolic parameters.

Further studies are needed to determine the long-term clinical significance of these changes and how mazdutide may compare with established treatments.

Important Information About Mazdutide

• Mazdutide is also known as IBI362.
• It is designed to activate GLP-1 and glucagon receptors.
• It has been developed for metabolic diseases including obesity and type 2 diabetes.
• Clinical studies have evaluated once-weekly administration.
• Multiple clinical trials have investigated different doses and treatment populations.
• Clinical development includes large Phase 3 studies.
• UK regulatory status should be checked directly with the MHRA before making availability claims.
• Unverified online products labelled mazdutide should not be used.
• Clinical-trial results do not guarantee individual treatment outcomes.

Frequently Asked Questions

What is mazdutide?

Mazdutide, also known as IBI362, is a long-acting dual GLP-1 and glucagon receptor agonist being developed for metabolic diseases including obesity and type 2 diabetes.

Is mazdutide a GLP-1 medicine?

Mazdutide activates the GLP-1 receptor but also activates the glucagon receptor, giving it a dual mechanism of action.

Is mazdutide the same as Ozempic?

No. Ozempic contains semaglutide, which is a GLP-1 receptor agonist. Mazdutide is a separate medicine designed to activate GLP-1 and glucagon receptors.

Is mazdutide the same as Mounjaro?

No. Mounjaro contains tirzepatide, which activates GIP and GLP-1 receptors. Mazdutide has GLP-1 and glucagon receptor activity.

Is mazdutide approved in the UK?

Mazdutide should not be described as a routine UK-authorised medicine unless current MHRA marketing-authorisation information confirms this. UK regulatory status should be checked before prescribing or availability claims are made.

Is mazdutide being studied for weight loss?

Yes. Mazdutide has been investigated extensively for overweight and obesity, including large clinical studies evaluating body-weight reduction and metabolic outcomes.

Is mazdutide an injection?

Mazdutide has been investigated as a once-weekly subcutaneous injectable medicine in clinical development.

Can I buy mazdutide online?

Consumers should not assume that products advertised online as mazdutide or IBI362 are authorised or authentic medicines. Regulatory status and product quality should always be verified.

Key Product Information

Product	Mazdutide / IBI362
Developer	Innovent Biologics / Eli Lilly collaboration
Drug type	Dual GLP-1 and glucagon receptor agonist
Route studied	Subcutaneous injection
Frequency studied	Once weekly
Research areas	Overweight, obesity and type 2 diabetes
Development	Advanced clinical development
MHRA – Medicines and Healthcare products Regulatory AgencyUK status	Check current MHRA authorisation before making availability claims

Authoritative Resources

MHRA – Marketing authorisations granted in 2026

ClinicalTrials.gov – Clinical Trial Database

Innovent Biologics – Official Website

Related Medicines

For information about other medicines in this therapeutic area, explore Mounjaro (tirzepatide), Ozempic (semaglutide), Rybelsus (semaglutide), our weight-management medicines, our diabetes medicines or our health and medicine blog.

Medical disclaimer: This page is for educational purposes only. Mazdutide is a medicine whose regulatory status varies by jurisdiction and should not be presented as a UK-authorised routine prescription product without confirmation from the MHRA. Always seek advice from a qualified healthcare professional.